Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles. Local targets link to admitted publications; unresolved targets remain external evidence.
CAR-T cell therapy in hematological malignancies: Current opportunities and challenges
2022 · External reference
CAR-T cell therapy embarks on autoimmune disease
10.1038/s41409-024-02429-6 · 2025 · External reference
CAR T-cell therapy in autoimmune diseases
10.1016/s0140-6736(23)01126-1 · 2023 · External reference
Harnessing chimeric antigen receptor (CAR)-T cells as a potential treatment for Alzheimer’s disease
10.18609/cgti.2023.132 · 2023 · External reference
CAR-T design: Elements and their synergistic function
10.1016/j.ebiom.2020.102931 · 2020 · External reference
Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
10.1186/s13287-020-01741-4 · 2020 · External reference
γδ T cells: origin and fate, subsets, diseases and immunotherapy
10.1038/s41392-023-01653-8 · 2023 · External reference
Engineered multicellular niches for pluripotent stem cell–derived immunotherapy
10.1016/j.cobme.2020.06.002 · 2020 · External reference
From bench to bedside: the history and progress of CAR T cell therapy
10.3389/fimmu.2023.1188049 · 2023 · External reference
Current progress in CAR-T cell therapy for hematological malignancies
10.7150/jca.48976 · 2021 · External reference
Accelerating and optimising CAR T-cell manufacture to deliver better patient products
10.1016/s2352-3026(24)00273-4 · 2025 · External reference
Counteracting CAR T cell dysfunction
10.1038/s41388-020-01501-x · 2021 · External reference
Beyond youth: Understanding CAR T cell fitness in the context of immunological aging
10.1016/j.smim.2023.101840 · 2023 · External reference
The intrinsic defects of T cells impact the efficacy of CAR-T therapy in patients with diffuse large B-cell lymphoma
10.1038/s41408-023-00958-9 · 2023 · External reference
Beyond the blood: expanding CAR T cell therapy to solid tumors
10.1038/s41587-024-02446-2 · 2025 · External reference
Enhancing the potency of CAR-T cells against solid tumors through transcription factor engineering
10.1172/jci.insight.193048 · 2025 · External reference
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
10.1038/s41571-024-00959-y · 2025 · External reference
“Off-the-shelf” allogeneic CAR T cells: development and challenges
10.1038/s41573-019-0051-2 · 2020 · External reference
Emerging trends in clinical allogeneic CAR cell therapy
10.1016/j.medj.2025.100677 · 2025 · External reference
Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells
10.1038/s41467-023-44176-0 · 2023 · External reference
Managing allorejection in off-the-shelf CAR-engineered cell therapies
10.1016/j.ymthe.2024.11.035 · 2025 · External reference
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial
10.1038/s41591-024-03282-2 · 2025 · External reference
Cell engineering with microfluidic squeezing preserves functionality of primary immune cells in vivo
10.1073/pnas.1809671115 · 2018 · External reference
Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering
10.1016/j.omtm.2023.101139 · 2023 · External reference
Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression
10.1136/jitc-2021-004446 · 2022 · External reference
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
10.1038/nature21405 · 2017 · External reference
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
10.1016/j.cell.2023.08.041 · 2023 · External reference
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome
10.1016/j.trecan.2025.08.001 · 2025 · External reference
Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells
10.1016/j.ymthe.2022.12.004 · 2023 · External reference
Base-edited CAR T cells for combinational therapy against T cell malignancies
10.1038/s41375-021-01282-6 · 2021 · External reference
Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia
10.1056/nejmoa2300709 · 2023 · External reference
Lipid nanoparticles allow efficient and harmless ex vivo gene editing of human hematopoietic cells
10.1182/blood.2022019333 · 2023 · External reference
Ionizable lipid nanoparticles with integrated immune checkpoint inhibition for mRNA CAR T cell engineering
10.1002/adhm.202301515 · 2023 · External reference
Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy
2024 · External reference
CAR T cells produced in vivo to treat cardiac injury
10.1126/science.abm0594 · 2022 · External reference
Efficient mRNA delivery to resting T cells to reverse HIV latency
10.1038/s41467-025-60001-2 · 2025 · External reference
Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging
2025 · External reference
IL7 increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation
10.1073/pnas.2319856121 · 2024 · External reference
IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype
10.1158/2326-6066.cir-18-0466 · 2019 · External reference
How transcription factors drive choice of the T cell fate
10.1038/s41577-020-00426-6 · 2021 · External reference
In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo
10.1038/s41467-020-19486-2 · 2020 · External reference
Transient EZH2 suppression by tazemetostat during in vitro expansion maintains T-cell stemness and improves adoptive T-cell therapy
10.1158/2326-6066.cir-24-0089 · 2025 · External reference
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
10.1126/science.aba1786 · 2021 · External reference
MRNA-based genetic reprogramming
10.1016/j.ymthe.2018.12.009 · 2019 · External reference
FOXO1 is a master regulator of memory programming in CAR T cells
10.1038/s41586-024-07300-8 · 2024 · External reference
Genome-wide CRISPR screen in human T cells reveals regulators of FOXP3
10.1038/s41586-025-08795-5 · 2025 · External reference
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
10.1186/s12943-022-01559-z · 2022 · External reference
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
10.1126/science.aab4077 · 2015 · External reference
Distinct temporal programming of naive CD4+ T cells for cell division versus TCR-dependent death susceptibility by antigen-presenting macrophages
10.1002/eji.200425635 · 2005 · External reference
High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing
10.1016/j.ymthe.2025.04.006 · 2025 · External reference
Lipid nanoparticles produce chimeric antigen receptor macrophages (CAR-M) in situ for the treatment of solid tumors
10.1016/j.nantod.2024.102610 · 2025 · External reference
Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers
10.1038/s41467-017-00505-8 · 2017 · External reference
Transient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells
10.1096/fj.14-259531 · 2015 · External reference
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy
10.1038/nbt.2678 · 2013 · External reference
Therapeutic applications of cell engineering using mRNA technology
10.1016/j.tibtech.2024.07.012 · 2025 · External reference
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction
10.1038/s43587-023-00560-5 · 2024 · External reference
Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells
10.1016/j.ymthe.2026.05.029 · 2026 · External reference
Senolytic CAR T cells reverse senescence-associated pathologies
10.1038/s41586-020-2403-9 · 2020 · External reference
Optimization of DOTAP/chol cationic lipid nanoparticles for mRNA, pDNA, and oligonucleotide delivery
10.1208/s12249-022-02294-w · 2022 · External reference
Enhancing CAR-NK cells against solid tumors through chemical and genetic fortification with DOTAP-functionalized lipid nanoparticles
2024 · External reference
Precondensed Plasmid DNA enhances CAR-T cell generation via lipid nanoparticles
10.1021/acsomega.5c04308 · 2025 · External reference
Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA
10.1038/s41434-019-0095-2 · 2019 · External reference
Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery
10.1038/s41596-022-00755-x · 2023 · External reference
DOTAP/DOPE ratio and cell type determine transfection efficiency with DOTAP-liposomes
10.1016/j.bbamem.2015.06.020 · 2015 · External reference
Exploration of mRNA nanoparticles based on DOTAP through optimization of the helper lipids
10.1002/biot.202300123 · 2023 · External reference
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
10.1038/s41586-020-2622-0 · 2020 · External reference
DOTAP: Structure, hydration, and the counterion effect
10.1016/j.bpj.2023.01.031 · 2023 · External reference
Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR-Cas9 ribonucleoprotein
10.1038/s41587-024-02437-3 · 2024 · External reference
Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models
10.1038/s41467-023-42948-2 · 2023 · External reference
The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA
10.1016/j.jconrel.2024.08.016 · 2024 · External reference
mRNA lipid nanoparticle formulation, characterization and evaluation
10.1038/s41596-024-01134-4 · 2025 · External reference
Macropinocytosis drives T cell growth by sustaining the activation of mTORC1
10.1038/s41467-019-13997-3 · 2020 · External reference
Endocytosis of gene delivery vectors: from clathrin-dependent to lipid raft-mediated endocytosis
10.1038/mt.2013.54 · 2013 · External reference
Cholesterol-dependent macropinocytosis and endosomal escape control the transfection efficiency of lipoplexes in CHO living cells
10.1021/mp200374e · 2012 · External reference
Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells
10.1186/s13059-023-02928-7 · 2023 · External reference
Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality
10.1038/s41598-023-45197-x · 2023 · External reference
Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors
10.1038/s41467-019-13007-6 · 2019 · External reference
Rapid, efficient and activation-neutral gene editing of polyclonal primary human resting CD4+ T cells allows complex functional analyses
10.1038/s41592-021-01328-8 · 2022 · External reference
Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease-engineered T cells
10.1073/pnas.2427216122 · 2025 · External reference
Efficient and non-genotoxic RNA-based engineering of human T cells using tumor-specific T cell receptors with minimal TCR mispairing
10.3389/fimmu.2018.02503 · 2018 · External reference
Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide
10.1073/pnas.1712963115 · 2018 · External reference
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
10.1038/nbt.3290 · 2015 · External reference
Optimized two-step electroporation process to achieve efficient nonviral-mediated gene insertion into primary T cells
10.1002/2211-5463.13292 · 2022 · External reference
Genome editing in engineered T cells for cancer immunotherapy
10.1089/hum.2023.128 · 2023 · External reference
On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles
10.1073/pnas.2109256118 · 2021 · External reference
Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation
10.1016/j.omtn.2026.102929 · 2026 · External reference
Elucidating lipid nanoparticle properties and structure through biophysical analyses
2025 · External reference
Toward a large-batch manufacturing process for silicon-stabilized lipid nanoparticles: A highly customizable RNA delivery platform
10.1016/j.omtm.2024.101299 · 2024 · External reference
Systematic optimization of siRNA productive uptake into resting and activated T cells ex vivo
10.1016/j.biopha.2024.116285 · 2024 · External reference
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
10.1021/acs.nanolett.9b04246 · 2020 · External reference
The mixing method used to formulate lipid nanoparticles affects mRNA delivery efficacy and organ tropism
10.1016/j.ejpb.2023.10.006 · 2023 · External reference
In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism
10.1002/smll.202304378 · 2024 · External reference
Cationic mRNA lipid nanoparticles for ex vivo NanoCAR-T cell engineering
10.1002/advs.202521507 · 2026 · External reference
Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
10.1038/s41541-023-00751-6 · 2023 · External reference
Review of structural design guiding the development of lipid nanoparticles for nucleic acid delivery
10.1016/j.cocis.2023.101705 · 2023 · External reference
Antigen presenting cell mimetic lipid nanoparticles for rapid mRNA CAR T cell cancer immunotherapy (adv. Mater. 26/2024)
2024 · External reference
The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
10.1016/j.isci.2021.103479 · 2021 · External reference
Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)
10.1016/j.jconrel.2021.12.027 · 2022 · External reference
Pro-inflammatory concerns with lipid nanoparticles
10.1016/j.ymthe.2022.04.011 · 2022 · External reference
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
10.1038/s41586-020-2814-7 · 2020 · External reference
Amine headgroups in ionizable lipids drive immune responses to lipid nanoparticles by binding to the receptors TLR4 and CD1d
10.1038/s41551-024-01256-w · 2024 · External reference
Customizable mRNA lipid nanoparticles for transfection of primary human T cells
10.1021/acsnano.5c15903 · 2025 · External reference
Ionizable lipid nanoparticles for therapeutic base editing of congenital brain disease
10.1021/acsnano.3c02268 · 2023 · External reference
Hydroxyapatite binding peptide lipid nanoparticles for biomimetic mRNA delivery to bone
2025 · External reference
A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
10.1016/j.omtn.2019.02.018 · 2019 · External reference
